Hyung-Jun Im
Assistant Professor & Chief Scientific Officer Seoul National University & Portal
Hyung-Jun Im, MD, PhD, is an Associate Professor at Seoul National University and Chief Scientific Officer of Portrai, a spatial biology-driven techbio company. Trained as a nuclear medicine physician-scientist, his research focuses on theranostic drug development and therapeutic optimization through molecular imaging and spatial biology. His group develops imaging-enabled and target-directed therapeutic platforms, including nanoparticle drug delivery systems, and radiotheranostics. He is Editor-in-Chief of Health Nanotechnology, Associate Editor of the Journal of Nanobiotechnology, a member of the Young Korean Academy of Science and Technology
Seminars
As lipid-based nanoparticles advance beyond the liver, developers across RNA, cell, and gene industries are re-evaluating their strategies to address payload delivery challenges. This is driving new innovations, novel chemistries and methods to improve toxicity profiles, potency and efficacy, while ensuring manufacturability at scale. This interactive workshop will explore the scientific, technical, and regulatory trade-offs shaping the future of extrahepatic LNP delivery.
Join this discussion to gain key insights on:
- Exploring novel LNP and nanoparticle targeting strategies from receptor targeting, antibody conjugation and organ-selective platforms to improve biodistribution, target specificity, and improve therapeutic efficacy
- Assessing the CMC and manufacturing challenges of complex LNP formulations to ensure stability and delivery efficiency
- Delving into toxicology and pharmacology of targeting moieties, potential biological interference, and exploring practical considerations for regulatory approval of targeted LNP system
